|
Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials. |
|
|
|
Consulting or Advisory Role - Boehringer Ingelheim; Novartis; Pfizer |
|
|
Honoraria - Bayer; Boehringer Ingelheim |
Consulting or Advisory Role - Bayer; Boehringer Ingelheim |
|
|
|
No Relationships to Disclose |
|
|
Employment - Boehringer Ingelheim |
|
|
Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Roche Pharma AG; Sanofi |
Consulting or Advisory Role - Novartis; Roche Pharma AG |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bayer |
|
Markus Peck-Radosavljevic |
No Relationships to Disclose |
|
|
Honoraria - Celgene; Daiichi Sankyo; Roche Pharma AG; Sanofi; Sirtex Medical |
Speakers' Bureau - Celgene; Roche Pharma AG; Sirtex Medical |
Research Funding - Sanofi |
Travel, Accommodations, Expenses - Celgene; Merck Serono; Roche Pharma AG; Sanofi; Sirtex Medical |
|
|
No Relationships to Disclose |
|
|
Employment - Boehringer Ingelheim |
|
|
No Relationships to Disclose |
|
|
Employment - Boehringer Ingelheim |
|
|
Honoraria - Bayer; Sanofi |
Consulting or Advisory Role - Chugai Pharma; Merck Serono; Sanofi |
Speakers' Bureau - Lilly; Novartis |
Research Funding - Chugai Pharma; Sanofi |